Core Viewpoint - The company expects a net profit attributable to shareholders of 70 million to 90 million yuan for the fiscal year 2025, representing a year-on-year growth of 241.55% to 339.13% [1] Group 1: Performance Drivers - The current performance change is attributed to the deepening of marketing transformation, advancement of brand strategy, and product recovery [1] - Core product sales have rebounded, and marketing channel optimization has contributed to a good recovery in both operating revenue and overall gross profit margin [1] Group 2: Financial Impact - Despite short-term impacts on profits due to investments in brand building, the overall operating profit has shown positive improvement [1] - The results reflect that marketing reforms and brand development have achieved significant effectiveness [1]

每经AI快讯，特一药业1月22日晚间发布业绩预告，预计2025年归属于上市公司股东的净利润7000万元 ~9000万元，同比增长241.55%~339.13%；基本每股收益0.14元~0.18元。业绩变动主要原因是，公司当 前业绩变化是营销转型深化、品牌战略推进与产品复苏共同作用的结果。在核心产品销量回升、营销渠 道优化等因素共同推动下，公司营业收入及综合毛利率均呈现较好恢复。尽管品牌建设投入短期内对利 润带来一定影响，但公司整体营业利润仍实现积极改善，反映出营销变革与品牌建设已取得较好成效。 每经头条（nbdtoutiao）——特朗普强要格陵兰岛，丹麦一养老基金率先清仓美债，美国资产全线下 跌！欧洲手握"金融核按钮"，双方会"鱼死网破"吗？专家解读→ （记者 王晓波） ...

Core Viewpoint - The company expects a net profit of 70 million to 90 million yuan for the year 2025, representing a year-on-year growth of 241.55% to 339.13% [1] Group 1: Performance Drivers - The performance change is attributed to the deepening of marketing transformation, advancement of brand strategy, and product recovery [1] - Core product sales have rebounded, and marketing channel optimization has contributed to a good recovery in both operating revenue and overall gross profit margin [1] Group 2: Financial Impact - Despite short-term impacts on profits due to investments in brand building, the overall operating profit has shown positive improvement [1] - The results reflect that marketing reform and brand development have achieved significant effectiveness [1]

Core Viewpoint - The company, Te Yi Pharmaceutical, anticipates a significant increase in net profit for the year 2025, driven by marketing transformation, brand strategy advancement, and product recovery [1] Financial Performance - The expected net profit attributable to shareholders for 2025 is projected to be between 70 million and 90 million yuan, representing a year-on-year increase of 241.55% to 339.13% [1] - The anticipated net profit after deducting non-recurring gains and losses is estimated to be between 67.5 million and 87.5 million yuan, reflecting a year-on-year growth of 263.83% to 371.64% [1] Business Strategy - The company's performance improvement is attributed to the recovery in core product sales and optimization of marketing channels [1] - Despite short-term impacts on profits due to investments in brand building, the overall operating profit has shown positive improvement, indicating successful outcomes from marketing reforms and brand development [1]